Medication info

Optima Eye Drops (Tobramycin)

Prescription medicationEye drops
Ingredient · strength
Tobramycin›3mg / 1mL
Manufacturer / importer
IYON Pharmaceutical Co., Ltd.
Appearance
A colorless to pale yellow eye drop solution in a clear plastic container [Export use] A colorless, transparent liquid in a clear plastic eye dropper.
Packaging
5mL/bottle, 6mL/bottle
Approval status
Active

MFDS item code 200000270 · Notified 2000.12.08 · Insurance code 658600902

Summary

Main use
Treatment of eye infections (conjunctivitis, keratitis, etc.) and systemic infections (pneumonia, etc.)
Who uses it
Adults · Children
Adult dosage
(Injection) Adults: For severe infections, administer 3mg (potency) of tobramycin per Kg of body weight per day in 3 divided doses by intravenous or intramuscular injection. For life-threatening infections, up to 5mg (potency) per Kg of body weight per day may be administered in 3~4 divided doses; when symptoms improve, the dose should be reduced to 3mg (potency) per Kg of body weight per day. Do not administer more than 5mg (potency) per Kg of body weight per day without measuring serum concentrations. Patients with renal failure Measure the serum concentration of this drug if possible. Administer an initial dose of 1mg (potency) per Kg of body weight, then reduce the dose or extend the dosing interval starting with the second dose. If the serum concentration of this drug cannot be measured directly, calculate the dose based on creatinine clearance or serum creatinine concentration, and adjust the dose while monitoring the patient's condition. However, these methods should not be used during dialysis. 1) Dose reduction (dosing interval 8 hours): If creatinine clearance is 70mL/min or less, or if the serum creatinine concentration is known, calculate the dose by multiplying the dose for a patient with normal renal function by the applicable % value in <Table 1>. If the patient's steady-state serum creatinine concentration is known, an approximate dose can be calculated by dividing the dose for a patient with normal renal function by the serum creatinine concentration. 2) Extension of the dosing interval (same dose as for patients with normal renal function): If the patient's creatinine clearance cannot be measured and the patient's condition is stable, administer doses at intervals calculated by multiplying the serum creatinine concentration by 6. (Eye drops) For mild to moderate infections, instill 1~2 drops into the infected area every 4 hours. For severe infections, instill 2 drops every hour until symptoms improve, then gradually reduce and discontinue. (Eye ointment) For mild to moderate infections, squeeze approximately 1cm into the infected area 2~3 times daily. For severe infections, apply 1cm to the infected area every 3~4 hours until symptoms improve, then gradually reduce and discontinue. Adjust the dose as appropriate according to age and symptoms. <Preparation of this drug> For intramuscular injection, dissolve in 1.5mL of normal saline for injection or Water for Injection before use. For intravenous injection in adults, dilute the dose in 50~100mL of normal saline for injection or 5% dextrose injection and administer by intravenous infusion over 20~60 minutes. It is preferable not to administer this drug mixed with other medicines.
Children's dosage
(Injection) Children: Administer 5mg (potency) per Kg of body weight per day in 3~4 divided doses by intravenous or intramuscular injection. Neonates (less than 1 week after birth): Administer 4mg (potency) per Kg of body weight per day in divided doses every 12 hours. The treatment period is usually 7~10 days and may be extended depending on the severity of the infection; in this case, monitor renal, vestibular, and auditory function (neurotoxicity occurs more frequently when the treatment period exceeds 10 days). For intravenous injection in children, reduce the volume of diluent proportionally. Avoid intravenous infusion over less than 20 minutes, as serum tobramycin concentrations may exceed 12mg/mL.

Ingredients

Manufacturer
IYON Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of eye infections (conjunctivitis, keratitis, etc.) and systemic infections (pneumonia, etc.)

  • Meningitis
  • central nervous system infections
  • bronchitis
  • bronchiectasis
  • pneumonia
  • peritonitis
  • gastrointestinal infections
  • subcutaneous abscesses
  • boils
  • soft tissue infections
  • burns
  • post-surgical wound infections
View approved original text

This medication, when used as an injection, is effective against various bacteria including Pseudomonas aeruginosa, Escherichia coli, and Staphylococcus aureus, and is used to treat meningitis, pneumonia, peritonitis, skin and soft tissue infections, burns and post-surgical infections, bone infections, sepsis, as well as severe pyelonephritis and cystitis. As eye drops or ointments, it responds to various ocular pathogens, including Staphylococcus aureus, Streptococcus, and Pseudomonas, and is used to treat blepharitis, dacryocystitis, styes, conjunctivitis, keratitis, and corneal ulcers. This drug is widely used to treat various bacterial infections, making it effective for multiple infectious diseases.

Dosage and Administration

Adult dosage

(Injection) Adults: For severe infections, administer 3mg (potency) of tobramycin per Kg of body weight per day in 3 divided doses by intravenous or intramuscular injection. For life-threatening infections, up to 5mg (potency) per Kg of body weight per day may be administered in 3~4 divided doses; when symptoms improve, the dose should be reduced to 3mg (potency) per Kg of body weight per day. Do not administer more than 5mg (potency) per Kg of body weight per day without measuring serum concentrations. Patients with renal failure Measure the serum concentration of this drug if possible. Administer an initial dose of 1mg (potency) per Kg of body weight, then reduce the dose or extend the dosing interval starting with the second dose. If the serum concentration of this drug cannot be measured directly, calculate the dose based on creatinine clearance or serum creatinine concentration, and adjust the dose while monitoring the patient's condition. However, these methods should not be used during dialysis. 1) Dose reduction (dosing interval 8 hours): If creatinine clearance is 70mL/min or less, or if the serum creatinine concentration is known, calculate the dose by multiplying the dose for a patient with normal renal function by the applicable % value in <Table 1>. If the patient's steady-state serum creatinine concentration is known, an approximate dose can be calculated by dividing the dose for a patient with normal renal function by the serum creatinine concentration. 2) Extension of the dosing interval (same dose as for patients with normal renal function): If the patient's creatinine clearance cannot be measured and the patient's condition is stable, administer doses at intervals calculated by multiplying the serum creatinine concentration by 6. (Eye drops) For mild to moderate infections, instill 1~2 drops into the infected area every 4 hours. For severe infections, instill 2 drops every hour until symptoms improve, then gradually reduce and discontinue. (Eye ointment) For mild to moderate infections, squeeze approximately 1cm into the infected area 2~3 times daily. For severe infections, apply 1cm to the infected area every 3~4 hours until symptoms improve, then gradually reduce and discontinue. Adjust the dose as appropriate according to age and symptoms. <Preparation of this drug> For intramuscular injection, dissolve in 1.5mL of normal saline for injection or Water for Injection before use. For intravenous injection in adults, dilute the dose in 50~100mL of normal saline for injection or 5% dextrose injection and administer by intravenous infusion over 20~60 minutes. It is preferable not to administer this drug mixed with other medicines.

Children's dosage

(Injection) Children: Administer 5mg (potency) per Kg of body weight per day in 3~4 divided doses by intravenous or intramuscular injection. Neonates (less than 1 week after birth): Administer 4mg (potency) per Kg of body weight per day in divided doses every 12 hours. The treatment period is usually 7~10 days and may be extended depending on the severity of the infection; in this case, monitor renal, vestibular, and auditory function (neurotoxicity occurs more frequently when the treatment period exceeds 10 days). For intravenous injection in children, reduce the volume of diluent proportionally. Avoid intravenous infusion over less than 20 minutes, as serum tobramycin concentrations may exceed 12mg/mL.

Precautions

This medication is an aminoglycoside antibiotic and should not be used in certain patients. For example, individuals allergic to this medication or similar antibiotics, or bacitracin should not use this drug. Furthermore, patients with ear diseases, very poor kidney function, women who are pregnant or breastfeeding, and those with muscle disorders should avoid this medication. Also, patients with bronchial asthma or certain neurological disorders should preferably not use this drug. When using this medication, special caution is advised for those with weak kidney or liver function, neonates or premature infants, the elderly, and individuals in poor nutritional status. This drug can rarely cause side effects such as allergic reactions, gastrointestinal disturbances, blood disorders, neurological disturbances, liver and kidney dysfunction, and skin rashes; if any abnormal symptoms appear, usage must be stopped immediately, and a doctor should be consulted. Particularly, this medication poses risks for hearing and kidney damage, so regular blood level and hearing tests are important during long-term or high-dose administration. Moreover, since this drug may interact with other medications, it is essential to inform your doctor or pharmacist if it will be used together with anesthetics, muscle relaxants, anticoagulants, or certain diuretics. During pregnancy or breastfeeding, this medication may be harmful to the fetus or neonate and should be used only if necessary; lactation should be paused during treatment. When using it as eye drops or ointment, do not inject directly into the eye, and discontinue use if irritation or allergic symptoms occur in the surrounding areas of the eye. Also, avoid wearing contact lenses during treatment, and be cautious when driving or operating machinery, as vision may be blurred. In case of overdose, kidney function decline, hearing damage, or difficulty breathing may occur, and immediate medical treatment should be sought.

Side effects

  • Shock
  • nausea
  • vomiting
  • loss of appetite
  • stomatitis
  • diarrhea
  • anemia
  • leukopenia
  • leukocytosis
  • granulocytosis
Show 61 more
  • eosinophilia
  • thrombocytopenia
  • dizziness
  • tinnitus
  • hearing loss
  • ear pain
  • sensation of ear blockage
  • lip numbness
  • limb numbness
  • drowsiness
  • headache
  • somnolence
  • delirium
  • local diminished sensation
  • heaviness
  • nonsensical speech
  • loss of directional sense
  • increased ALT
  • increased AST
  • increased serum LDH
  • increased bilirubin
  • jaundice
  • acute renal failure
  • edema
  • elevated BUN
  • elevated NPN
  • elevated serum creatinine
  • oliguria
  • proteinuria
  • hematuria
  • decreased serum calcium
  • decreased serum magnesium
  • decreased serum potassium
  • decreased serum sodium
  • exfoliative dermatitis
  • toxic epidermal necrolysis
  • erythema multiforme
  • Stevens-Johnson syndrome
  • rash
  • urticaria
  • itching
  • erythema
  • fever
  • hypoprothrombinemia
  • bleeding tendency
  • glossitis
  • neuritis
  • injection site pain
  • injection site induration
  • injection site inflammation
  • phlebitis
  • overgrowth of resistant bacteria
  • eyelid itching
  • eyelid swelling
  • redness
  • erythematous conjunctivitis
  • temporary burning sensation in the eyes
  • irritation pain
  • irritation sensation
  • punctate keratopathy
  • increased tearing

Not everyone experiences these, and they can vary from person to person.

Storage

This medication can be sensitive to air and moisture, so it must be stored in a tightly sealed container. Additionally, it should be kept at room temperature, not too hot or cold, ideally between 1 degree and 30 degrees Celsius. Storing it this way will help maintain the drug's effectiveness for a longer period.

Appearance and packaging

Appearance

A colorless to pale yellow eye drop solution in a clear plastic container [Export use] A colorless, transparent liquid in a clear plastic eye dropper.

Package unit

5mL/bottle, 6mL/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.